AcelRx Pharmaceuticals

375 articles with AcelRx Pharmaceuticals

• AcelRx Pharmaceuticals Sufentanil NanoTab PCA System (ARX-01) Phase 2 Results Featured in Poster Presentations at the 35th Annual Meeting of the American Society of Regional Anesthesia and Pain

  4/20/2010

• AcelRx Pharmaceuticals Names Richard King Chief Executive Officer

  4/6/2010

• AcelRx Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management

  10/30/2009

• AcelRx Pharmaceuticals Announces Positive Results from a Phase 2 Study of ARX-03, a Sufentanil/Triazolam NanoTab for Procedural Sedation, Anxiolysis & Analgesia

  10/22/2009

• AcelRx Pharmaceuticals Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting

  10/15/2009

• AcelRx Pharmaceuticals Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009

  10/15/2009

• AcelRx Pharmaceuticals Hires Nigel Ray as Vice President of Business Development

  10/14/2009

• AcelRx Pharmaceuticals Announces Perfect Performance of Handheld Component of ARX-01 Sufentanil NanoTab PCA System in a Phase 2 Study

  7/22/2009

• AcelRx Pharmaceuticals Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

  6/29/2009

• AcelRx Pharmaceuticals Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System

  5/5/2009

• AcelRx Pharmaceuticals Announces Initiation of Phase 2 Cancer Breakthrough Pain Program

  4/22/2009

• AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations

  3/6/2009

• AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety

  1/13/2009

• AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development

  1/8/2009

• AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain Proof-of-Concept; Study Achieved Primary and Secondary Endpoints

  12/9/2008